Bile Duct Cancer (Cholangiocarcinoma) – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Bile Duct Cancer (Cholangiocarcinoma) – Pipeline Review, H2 2019’, provides an overview of the Bile Duct Cancer (Cholangiocarcinoma) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma)

The report reviews pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Bile Duct Cancer (Cholangiocarcinoma) therapeutics and enlists all their major and minor projects

The report assesses Bile Duct Cancer (Cholangiocarcinoma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

AbbVie Inc

AbGenomics International Inc

Ability Pharmaceuticals SL

ABM Therapeutics Inc

Advenchen Laboratories LLC

Agios Pharmaceuticals Inc

Alphamab Oncology

Andes Biotechnologies

Apollomics Inc

ArQule Inc

Ascelia Pharma AB

Aslan Pharmaceuticals Ltd

AstraZeneca Plc

Bavarian Nordic A/S

Bayer AG

BeiGene Ltd

Betta Pharmaceuticals Co Ltd

BioMed Valley Discoveries Inc

Boehringer Ingelheim International GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Co

Celldex Therapeutics Inc

Cellestia Biotech AG

Celltrion Inc

Celon Pharma SA

Clovis Oncology Inc

Coherent Biopharma

Convalife

Corcept Therapeutics Inc

CSPC Pharmaceutical Group Ltd

CStone Pharmaceuticals Co Ltd

Curegenix Inc

CytomX Therapeutics Inc

Daiichi Sankyo Co Ltd

Debiopharm International SA

Delcath Systems Inc

Delta-Fly Pharma Inc

Eddingpharm Inc

Eisai Co Ltd

Eli Lilly and Co

Exelixis Inc

F. Hoffmann-La Roche Ltd

Faron Pharmaceuticals Oy

Forma Therapeutics Inc

Fujifilm Holdings Corp

Genentech Inc

Genoscience Pharma

GlaxoSmithKline Plc

GO Therapeutics Inc

Guangdong Zhongsheng Pharmaceutical Co Ltd

H3 Biomedicine Inc

Harbin Gloria Pharmaceuticals Co Ltd

Hutchison MediPharma Ltd

ImCare Biotech LLC

Immunitor Inc

Incyte Corp

Inmune Bio Inc

InnoCare Pharma Ltd

Innopharmax Inc

Intensity Therapeutics Inc

Ipsen SA

J-Pharma Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Kangen Pharmaceuticals Co Ltd

Karus Therapeutics Ltd

Komipharm International Co Ltd

Leap Therapeutics Inc

Lexicon Pharmaceuticals Inc

Lokon Pharma AB

Luzitin SA

Marino Biotechnology Co Ltd

Mebiopharm Co Ltd

MediciNova Inc

Medivir AB

Merck & Co Inc

Merck KGaA

Mina Therapeutics Ltd

Molecular Templates Inc

Mundipharma EDO GmbH

Nanjing Transthera Biosciences Co Ltd

NanoCarrier Co Ltd

Newish Technology Beijing Co Ltd

Nkarta Inc

Northwest Biotherapeutics Inc

Novartis AG

NuCana Plc

Oasmia Pharmaceutical AB

Oncocross Co Ltd

OncoTherapy Science Inc

Ono Pharmaceutical Co Ltd

Orgenesis Inc

PCI Biotech Holding ASA

Pfizer Inc

Pharma Mar SA

Provecs Medical GmbH

Puma Biotechnology Inc

Puretech Health Plc

QED Therapeutics Inc

Rafael Pharmaceuticals Inc

RedHill Biopharma Ltd

Redx Pharma Plc

RemeGen Ltd

Rgenix Inc

Samyang Holdings Corp

Sanofi

Seald AS

Senhwa Biosciences Inc

Sensei Biotherapeutics Inc

Shanghai Haihe Biopharma Co Ltd

Shanghai Junshi Bioscience Co Ltd

Sichuan Kelun Pharmaceutical Co Ltd

Sillajen Biotherapeutics

Sinocelltech Ltd

Sirnaomics Inc

SMT bio Co Ltd

Sorrento Therapeutics Inc

Starpharma Holdings Ltd

Sun Pharma Advanced Research Company Ltd

SupremeCure Pharma Inc

SynCore Biotechnology Co Ltd

Syndax Pharmaceuticals Inc

SyntheX Inc

Taiho Pharmaceutical Co Ltd

Takeda Pharmaceutical Co Ltd

TCR2 Therapeutics Inc

tella Inc

Tempest Therapeutics Inc

Therillia Development Co Inc

Toray Industries Inc

TOT Biopharm Co Ltd

VasGene Therapeutics Inc

Xencor Inc

Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd

Zymeworks Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Bile Duct Cancer (Cholangiocarcinoma) - Overview 7

Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Development 8

Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Assessment 24

Bile Duct Cancer (Cholangiocarcinoma) - Companies Involved in Therapeutics Development 38

Bile Duct Cancer (Cholangiocarcinoma) - Drug Profiles 74

Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects 824

Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products 827

Bile Duct Cancer (Cholangiocarcinoma) - Product Development Milestones 828

Appendix 839

List of Tables

List of Tables

Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..5), H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by 4SC AG, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by AbbVie Inc, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by AbGenomics International Inc, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Ability Pharmaceuticals SL, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by ABM Therapeutics Inc, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Advenchen Laboratories LLC, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Agios Pharmaceuticals Inc, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Alphamab Oncology, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Andes Biotechnologies, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Apollomics Inc, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by ArQule Inc, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Ascelia Pharma AB, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Aslan Pharmaceuticals Ltd, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by AstraZeneca Plc, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Bavarian Nordic A/S, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Bayer AG, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by BeiGene Ltd, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Betta Pharmaceuticals Co Ltd, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by BioMed Valley Discoveries Inc, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Boehringer Ingelheim International GmbH, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Boston Biomedical Inc, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Bristol-Myers Squibb Co, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Celldex Therapeutics Inc, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Cellestia Biotech AG, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Celltrion Inc, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Celon Pharma SA, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Clovis Oncology Inc, H2 2019

Bile Duct Cancer (Cholangiocarcinoma) – Pipeline by Coherent Biopharma, H2 2019

List of Figures

List of Figures

Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports